Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...
While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...
Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...